These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 17125256)

  • 41. Conjugates of desferrioxamine B (DFOB) with derivatives of adamantane or with orally available chelators as potential agents for treating iron overload.
    Liu J; Obando D; Schipanski LG; Groebler LK; Witting PK; Kalinowski DS; Richardson DR; Codd R
    J Med Chem; 2010 Feb; 53(3):1370-82. PubMed ID: 20041672
    [TBL] [Abstract][Full Text] [Related]  

  • 42. A non-human primate model for the study of oral iron chelators.
    Wolfe LC; Nicolosi RJ; Renaud MM; Finger J; Hegsted M; Peter H; Nathan DG
    Br J Haematol; 1989 Jul; 72(3):456-61. PubMed ID: 2765410
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Comparison of clinically used and experimental iron chelators for protection against oxidative stress-induced cellular injury.
    Bendova P; Mackova E; Haskova P; Vavrova A; Jirkovsky E; Sterba M; Popelova O; Kalinowski DS; Kovarikova P; Vavrova K; Richardson DR; Simunek T
    Chem Res Toxicol; 2010 Jun; 23(6):1105-14. PubMed ID: 20521781
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Design, synthesis, and evaluation of novel 2-substituted 3-hydroxypyridin-4-ones: structure-activity investigation of metalloenzyme inhibition by iron chelators.
    Liu ZD; Kayyali R; Hider RC; Porter JB; Theobald AE
    J Med Chem; 2002 Jan; 45(3):631-9. PubMed ID: 11806714
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Esters and lactones of phenolic amino carboxylic acids: prodrugs for iron chelation.
    Pitt CG; Bao Y; Thompson J; Wani MC; Rosenkrantz H; Metterville J
    J Med Chem; 1986 Jul; 29(7):1231-7. PubMed ID: 3806573
    [TBL] [Abstract][Full Text] [Related]  

  • 46. HBED ligand: preclinical studies of a potential alternative to deferoxamine for treatment of chronic iron overload and acute iron poisoning.
    Bergeron RJ; Wiegand J; Brittenham GM
    Blood; 2002 Apr; 99(8):3019-26. PubMed ID: 11929795
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Asymmetric synthesis and biological evaluations of (+)- and (-)-6-dimethoxymethyl-1,4-dihydropyridine-3-carboxylic acid derivatives blocking N-type calcium channels.
    Yamamoto T; Ohno S; Niwa S; Tokumasu M; Hagihara M; Koganei H; Fujita S; Takeda T; Saitou Y; Iwayama S; Takahara A; Iwata S; Shoji M
    Bioorg Med Chem Lett; 2011 Jun; 21(11):3317-9. PubMed ID: 21514827
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Synthesis, physicochemical characterization, and biological evaluation of 2-(1'-hydroxyalkyl)-3-hydroxypyridin-4-ones: novel iron chelators with enhanced pFe(3+) values.
    Liu ZD; Khodr HH; Liu DY; Lu SL; Hider RC
    J Med Chem; 1999 Nov; 42(23):4814-23. PubMed ID: 10579844
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Significance of asymmetric sites in choosing siderophores as deferration agents.
    Bergeron RJ; Xin MG; Weimar WR; Smith RE; Wiegand J
    J Med Chem; 2001 Jul; 44(15):2469-78. PubMed ID: 11448229
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Drug evaluation: deferitrin (GT-56-252; NaHBED) for iron overload disorders.
    Barton JC
    IDrugs; 2007 Apr; 10(4):270-81. PubMed ID: 17390251
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Novel orally active iron chelators (3-hydroxypyridin-4-ones) enhance the biliary excretion of plasma non-transferrin-bound iron in rats.
    Zanninelli G; Choudury R; Loréal O; Guyader D; Lescoat G; Arnaud J; Verna R; Cosson B; Singh S; Hider RC; Brissot P
    J Hepatol; 1997 Jul; 27(1):176-84. PubMed ID: 9252093
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Iron chelators: in vitro inhibitory effect on the liver stage of rodent and human malaria.
    Stahel E; Mazier D; Guillouzo A; Miltgen F; Landau I; Mellouk S; Beaudoin RL; Langlois P; Gentilini M
    Am J Trop Med Hyg; 1988 Sep; 39(3):236-40. PubMed ID: 3052118
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Selection of a new generation of orally active alpha-ketohydroxypyridine iron chelators intended for use in the treatment of iron overload.
    Kontoghiorghes GJ; Barr J; Nortey P; Sheppard L
    Am J Hematol; 1993 Apr; 42(4):340-9. PubMed ID: 8493983
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Protection against oxidative damage by iron chelators: effect of lipophilic analogues and prodrugs of N,N'-bis(3,4,5-trimethoxybenzyl)ethylenediamine- N,N'-diacetic acid (OR10141).
    Galey JB; Destrée O; Dumats J; Génard S; Tachon P
    J Med Chem; 2000 Apr; 43(7):1418-21. PubMed ID: 10753479
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Structure-activity relationships of novel iron chelators for the treatment of iron overload disease: the methyl pyrazinylketone isonicotinoyl hydrazone series.
    Kalinowski DS; Sharpe PC; Bernhardt PV; Richardson DR
    J Med Chem; 2008 Jan; 51(2):331-44. PubMed ID: 18159922
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Iron distribution and histopathological characterization of the liver and heart of β-thalassemic mice with parenteral iron overload: Effects of deferoxamine and deferiprone.
    Yatmark P; Morales NP; Chaisri U; Wichaiyo S; Hemstapat W; Srichairatanakool S; Svasti S; Fucharoen S
    Exp Toxicol Pathol; 2014 Sep; 66(7):333-43. PubMed ID: 24907196
    [TBL] [Abstract][Full Text] [Related]  

  • 57. A comparison of the iron-clearing properties of parabactin and desferrioxamine.
    Bergeron R; Streiff RR; King W; Daniels RD; Wiegand J
    Blood; 1993 Oct; 82(8):2552-7. PubMed ID: 8400302
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Protection against hydrogen peroxide-mediated cytotoxicity in Friedreich's ataxia fibroblasts using novel iron chelators of the 2-pyridylcarboxaldehyde isonicotinoyl hydrazone class.
    Lim CK; Kalinowski DS; Richardson DR
    Mol Pharmacol; 2008 Jul; 74(1):225-35. PubMed ID: 18424550
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Synthesis, physicochemical properties and biological evaluation of aromatic ester prodrugs of 1-(2'-hydroxyethyl)-2-ethyl-3-hydroxypyridin-4-one (CP102): orally active iron chelators with clinical potential.
    Liu ZD; Liu DY; Lu SL; Hider RC
    J Pharm Pharmacol; 1999 May; 51(5):555-64. PubMed ID: 10411215
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Design, synthesis, and biological evaluation of aromatic ester prodrugs of 1-(3'-hydroxypropyl)-2-methyl-3-hydroxypyridin-4-one (CP41) as orally active iron chelators.
    Liu ZD; Liu DY; Lu SL; Hider RC
    Arzneimittelforschung; 2000 May; 50(5):461-70. PubMed ID: 10858874
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.